Headquartered in Boston, MA Fiscal year ends December NASDAQ: SPTX seaporttx.com
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other neuropsychiatric disorders. The company uses its proprietary Glyph platform to identify clinically validated mechanisms with established efficacy and safety that have historically been limited by high first-pass metabolism, low bioavailability, and/or side effects, and then applies its platform to overcome those limitations and create innovative oral therapies. Its pipeline includes GlyphAllo (SPT-300) for major depressive disorder, currently in a Phase 2b trial; GlyphAgo (SPT-320) for generalized anxiety disorder, advancing into Phase 2 development; and Glyph2BLSD (SPT-348), a non-hallucinogenic neuroplastogen in preclinical development for neuropsychiatric and headache disorders. The company completed its IPO in May 2026, raising $260 million in gross proceeds, and trades on the Nasdaq. Updated
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who…
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other neuropsychiatric disorders.
The Wall Street consensus 12-month price target for SPTX is $37.00.
